| Julie Christine Thies, NP | |
|
1201 N Erie St, Lexington, NE 68850-1560 | |
| (308) 324-5651 | |
| (308) 324-8359 |
| Full Name | Julie Christine Thies |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 10 Years |
| Location | 1201 N Erie St, Lexington, Nebraska |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346645447 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LW0102X | Nurse Practitioner - Women's Health | 53-76378-091 (Kansas) | Secondary |
| 363L00000X | Nurse Practitioner | 112356 (Nebraska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mary Lanning Healthcare | Hastings, NE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Obstetricians And Gynecologists Pc | 1951312024 | 10 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen/Pfizer's Enbrel is the leading tumor necrosis factor -alpha inhibitor prescribed in newly diagnosed rheumatoid arthritis patients, outpacing Abbott's Humira in the first three lines of treatment.
Researchers at the University in San Francisco, California, report that coronavirus disease 2019 (COVID-19) is unlikely to negatively impact on pregnancy-related outcomes such as premature birth, transmission to babies via breast milk, and infertility.
Researchers from John Hopkins University have created an innovative piece of optical imaging equipment for use on-board the Xstrahl Small Animal Radiation Research Platform.
A new review indicates that subjective well-being—factors such as life satisfaction and enjoyment of life—can influence physical health. The review's investigators also examine why this is so and conditions where it is most likely to occur.
Ventrus Biosciences Inc., a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the pricing of its initial public offering of 2,900,000 shares at $6.00 per share. The shares are expected to begin trading tomorrow, December 17, 2010 on the Nasdaq Capital Market under the symbol "VTUS". In addition, Ventrus has granted the underwriters a 45-day option to purchase up to an additional 435,000 shares to cover over-allotments, if any.
› Verified 7 days ago
| Entity Name | Lexington Regional Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316016165 PECOS PAC ID: 2860415874 Enrollment ID: O20060105000221 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen/Pfizer's Enbrel is the leading tumor necrosis factor -alpha inhibitor prescribed in newly diagnosed rheumatoid arthritis patients, outpacing Abbott's Humira in the first three lines of treatment.
Researchers at the University in San Francisco, California, report that coronavirus disease 2019 (COVID-19) is unlikely to negatively impact on pregnancy-related outcomes such as premature birth, transmission to babies via breast milk, and infertility.
Researchers from John Hopkins University have created an innovative piece of optical imaging equipment for use on-board the Xstrahl Small Animal Radiation Research Platform.
A new review indicates that subjective well-being—factors such as life satisfaction and enjoyment of life—can influence physical health. The review's investigators also examine why this is so and conditions where it is most likely to occur.
Ventrus Biosciences Inc., a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the pricing of its initial public offering of 2,900,000 shares at $6.00 per share. The shares are expected to begin trading tomorrow, December 17, 2010 on the Nasdaq Capital Market under the symbol "VTUS". In addition, Ventrus has granted the underwriters a 45-day option to purchase up to an additional 435,000 shares to cover over-allotments, if any.
› Verified 7 days ago
| Entity Name | Obstetricians & Gynecologists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851371892 PECOS PAC ID: 1951312024 Enrollment ID: O20060606000166 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen/Pfizer's Enbrel is the leading tumor necrosis factor -alpha inhibitor prescribed in newly diagnosed rheumatoid arthritis patients, outpacing Abbott's Humira in the first three lines of treatment.
Researchers at the University in San Francisco, California, report that coronavirus disease 2019 (COVID-19) is unlikely to negatively impact on pregnancy-related outcomes such as premature birth, transmission to babies via breast milk, and infertility.
Researchers from John Hopkins University have created an innovative piece of optical imaging equipment for use on-board the Xstrahl Small Animal Radiation Research Platform.
A new review indicates that subjective well-being—factors such as life satisfaction and enjoyment of life—can influence physical health. The review's investigators also examine why this is so and conditions where it is most likely to occur.
Ventrus Biosciences Inc., a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the pricing of its initial public offering of 2,900,000 shares at $6.00 per share. The shares are expected to begin trading tomorrow, December 17, 2010 on the Nasdaq Capital Market under the symbol "VTUS". In addition, Ventrus has granted the underwriters a 45-day option to purchase up to an additional 435,000 shares to cover over-allotments, if any.
› Verified 7 days ago
| Entity Name | Lexington Regional Health Center |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1467417352 PECOS PAC ID: 2860415874 Enrollment ID: O20071129000331 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen/Pfizer's Enbrel is the leading tumor necrosis factor -alpha inhibitor prescribed in newly diagnosed rheumatoid arthritis patients, outpacing Abbott's Humira in the first three lines of treatment.
Researchers at the University in San Francisco, California, report that coronavirus disease 2019 (COVID-19) is unlikely to negatively impact on pregnancy-related outcomes such as premature birth, transmission to babies via breast milk, and infertility.
Researchers from John Hopkins University have created an innovative piece of optical imaging equipment for use on-board the Xstrahl Small Animal Radiation Research Platform.
A new review indicates that subjective well-being—factors such as life satisfaction and enjoyment of life—can influence physical health. The review's investigators also examine why this is so and conditions where it is most likely to occur.
Ventrus Biosciences Inc., a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the pricing of its initial public offering of 2,900,000 shares at $6.00 per share. The shares are expected to begin trading tomorrow, December 17, 2010 on the Nasdaq Capital Market under the symbol "VTUS". In addition, Ventrus has granted the underwriters a 45-day option to purchase up to an additional 435,000 shares to cover over-allotments, if any.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Julie Christine Thies, NP Po Box 980, Lexington, NE 68850-0980 Ph: (308) 324-5651 | Julie Christine Thies, NP 1201 N Erie St, Lexington, NE 68850-1560 Ph: (308) 324-5651 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen/Pfizer's Enbrel is the leading tumor necrosis factor -alpha inhibitor prescribed in newly diagnosed rheumatoid arthritis patients, outpacing Abbott's Humira in the first three lines of treatment.
Researchers at the University in San Francisco, California, report that coronavirus disease 2019 (COVID-19) is unlikely to negatively impact on pregnancy-related outcomes such as premature birth, transmission to babies via breast milk, and infertility.
Researchers from John Hopkins University have created an innovative piece of optical imaging equipment for use on-board the Xstrahl Small Animal Radiation Research Platform.
A new review indicates that subjective well-being—factors such as life satisfaction and enjoyment of life—can influence physical health. The review's investigators also examine why this is so and conditions where it is most likely to occur.
Ventrus Biosciences Inc., a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the pricing of its initial public offering of 2,900,000 shares at $6.00 per share. The shares are expected to begin trading tomorrow, December 17, 2010 on the Nasdaq Capital Market under the symbol "VTUS". In addition, Ventrus has granted the underwriters a 45-day option to purchase up to an additional 435,000 shares to cover over-allotments, if any.
› Verified 7 days ago
Stephanie L Reutlinger, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1201 N Erie St, Lexington, NE 68850 Phone: 308-324-5651 Fax: 308-324-8359 | |
Travis L Barkmeier, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1201 N Erie St, Lexington, NE 68850 Phone: 308-324-5651 Fax: 308-324-8359 | |
Kaitlyn M Lemmer, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1201 N Erie St, Lexington, NE 68850 Phone: 308-324-5651 Fax: 308-324-8359 | |
Raime L Misko, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1201 N Erie St, Lexington, NE 68850 Phone: 308-324-5651 Fax: 308-324-8359 | |
Barbara J Foss, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1201 N Erie St, Lexington, NE 68850 Phone: 308-324-5651 Fax: 308-324-8359 | |
Nicole C Thorell, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1201 N Erie St, Lexington, NE 68850 Phone: 308-324-5651 Fax: 308-324-8359 |